Radioimmunoassay for fluphenazine sulfoxide in human plasma.
K K Midha, E M Hawes, J W Hubbard, G McKay, G Rauw, M S Sardessai, M Aravagiri, M D Moore
Index: J. Pharmacol. Methods 19(1) , 63-74, (1988)
Full Text: HTML
Abstract
Antisera to fluphenazine sulfoxide were raised in New Zealand white rabbits to an immunogen synthesized by covalent linkage of bovine serum albumin to 10-[[3-[4-(4-carboxybutyl)-1-piperazinyl] propyl]]-2-trifluoromethyl-10H-phenothiazine 5-sulfoxide. With use of an antiserum, a radioimmunoassay for fluphenazine sulfoxide was developed that is able to quantitate 0.156 ng ml-1 using only a 200 microliter plasma sample with a coefficient of variation less than 5%. The antiserum had negligible cross-reactivities to fluphenazine (less than 1%) and its important metabolites, such as fluphenazine N4'-oxide (1%), 7-hydroxyfluphenazine (less than 1%), and N4'-deshydroxy-ethylfluphenazine (1%). The cross-reactivities with structurally similar phenothiazine 5-sulfoxides, such as those of trifluoperazine, prochlorperazine, perphenazine, and N4'-deshydroxyethylfluphenazine, were considerable, such that the antiserum can be used to develop a quantitative radioimmunoassay for any of these compounds. The reported radioimmunoassay was found to be suitable and adequate to quantitate fluphenazine sulfoxide in the plasma of patients treated with oral or intramuscular fluphenazine.
Related Compounds
Related Articles:
1991-05-01
[Br. J. Psychiatry 158 , 658-65, (1991)]
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
1994-07-01
[J. Psychiatry Neurosci. 19(4) , 254-64, (1994)]
The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.
1987-01-01
[Psychopharmacology 93(3) , 369-73, (1987)]